中国神经再生研究(英文版) ›› 2021, Vol. 16 ›› Issue (11): 2215-2216.doi: 10.4103/1673-5374.310688

• 观点:退行性病与再生 • 上一篇    下一篇

聚糖可提高蛋白质聚集抑制剂的功效和溶解度

  


  • 出版日期:2021-11-15 发布日期:2021-04-13

Glycans to improve efficacy and solubility of protein aggregation inhibitors

Ashim Paul, Daniel Segal, Elsa Zacco   

  1. Department of Molecular Microbiology and Biotechnology, Shmunis School of Biomedicine and Cancer Research, Tel Aviv University, Ramat Aviv, Tel Aviv 6997801, Israel (Paul A, Segal D)
    RNA Central Lab, Center for Human Technologies, Istituto Italiano di Tecnologia, 16152 Genova, Italy (Zacco E) 
  • Online:2021-11-15 Published:2021-04-13
  • Contact: Elsa Zacco, PhD, elsa.zacco@iit.it.
  • Supported by:
    The present work was partially supported by the Israel Ministry of Science and the Alliance Family Trust (to DS). AP is recipient of a fellowship from the Aufzien Family Center for the Prevention and Treatment of Parkinson’s Disease (APPD). EZ has received funding from the MINDED fellowship of the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No. 754490. 

摘要:

Neural Regen Res:聚糖对蛋白质稳定性和溶解性的有益作用可能提高血脑屏障渗透性和代谢稳定性

     由于对聚糖作用的详细机制尚不完全了解,有人提出,用碳水化合物修饰蛋白质主链可以导致替代的,更稳定的构象,从而减少了可通过聚合作用产生的易于聚集的物种数量。此外,由于它们的氢:氧比,碳水化合物可以扩大与溶剂的相互作用次数,从而增加蛋白质的溶解度。假定聚糖的吡喃环可以通过提供空间位阻和阻止单体自组装成致病性淀粉样物质所需的早期事件来干扰芳香族相互作用。聚糖对蛋白质稳定性和溶解度的这些有益作用已在体外得到利用,以减轻淀粉样蛋白的聚集。一种方法以PHF6为例,PHF6是一种高度聚合的合成六肽,衍生自全长tau,概括了野生型蛋白的聚集行为。PHF6的糖基化衍生物在体外表现出增强的溶解度和减弱的聚集倾向。

     来自意大利技术学院的Elsa Zacco团队认为聚糖化学作用提供的大量变体为设计新颖的强力小分子提供了丰富的资源,这些分子靶向各种疾病中的淀粉样蛋白聚集。单单元聚糖与芳香族氨基酸的结合,代表着有希望的未来蛋白质聚集抑制剂。为了扩展这类新的抑制剂,可以探索不同于色氨酸的其他芳香族氨基酸,例如苯丙氨酸,酪氨酸及其非蛋白衍生物。为了进一步改进这些新颖的基于芳香族氨基酸的抑制剂,可以进一步利用显示特定功能(例如抗氧化能力或与特定受体结合的能力)的聚糖的缀合来创建既起蛋白质聚集抑制剂作用又解决其他问题的分子。在相同靶向疾病的治疗方面,据我们所知,尚未在动物模型中测试过这种混合物。但是,与目前使用的蛋白质聚集小分子抑制剂相比,通过药物和组合化学技术的进一步优化,这些小分子可以获得更高的生物利用度,血脑屏障渗透性和代谢稳定性。

    文章《中国神经再生研究(英文版)》杂志202111 11  期发表。

https://orcid.org/0000-0002-3593-6023 (Elsa Zacco)

Abstract: Misfolding and subsequent aberrant self-assembly of certain proteins into toxic amyloid deposits are hallmarks of various diseases, most notably neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (Chiti and Dobson, 2017). Aromatic residues in amyloidogenic proteins have been shown to be key factors in protein oligomerization and fibrilization, mostly driven by π-π interactions. Together with aromaticity, post-translational modifications can greatly affect a protein’s solubility and conformation and, as a consequence, its propensity to aggregate. Among post-translational modifications, this perspective focuses on protein glycosylation, the decoration of a protein with carbohydrate motifs, its effect on amyloid formation and its employment in the inhibition of protein aggregation.